Erasca (NASDAQ: ERAS) — Perfil da empresa, notícias e dados financeiros
Erasca is a biotech firm dedicated to developing novel cancer therapies, focusing on improving outcomes through innovation.
Erasca
Erasca (NASDAQ:ERAS) is a dedicated biotech firm focused on the bold mission of eradicating cancer. The company’s operations revolve around developing novel therapies aimed at tackling various forms of cancer, pushing the boundaries of medical research to bring innovative treatments to patients in need. Erasca's projects span a wide range of oncology targets, employing cutting-edge science to disrupt cancerous processes and improve outcomes. Objectives center on advancing these therapies through clinical trials, maintaining a sharp focus on safety and efficacy to potentially transform cancer treatment paradigms. Through collaboration, rigorous research, and a passion for healing, Erasca is committed to making a significant impact in the fight against cancer.
Resumo
Operações
Produtos e/ou serviços de Erasca
- ERAS-007: An oral ERK1/2 inhibitor for treating RAS/MAPK pathway-driven cancers, targeting advanced solid tumors.
- ERAS-601: A selective SHP2 inhibitor aimed at enhancing anti-tumor immunity and overcoming resistance in cancer therapy.
- ERAS-801: An EGFR inhibitor tailored for treating EGFR-driven malignancies, including non-small cell lung cancer (NSCLC).
- HER3-DXd: An antibody-drug conjugate targeting HER3 for patients with solid tumors expressing HER3.
- RMC-6291: A RAS(ON) inhibitor focusing on RAS mutations prevalent in various cancers, developed in collaboration with Revolution Medicines.
- RMC-9805: A KRASG12D(ON) inhibitor, part of the collaboration with Revolution Medicines, intended for treating KRAS G12D-mutant cancers.
equipe executiva do Erasca
- Jonathan E. LimCo-Founder, Chairman & CEO
- David M. ChackoCFO & Chief Business Officer
- Michael D. VarneyChairman of Research & Development, Scientific Advisory Board Member and Director
- Shannon R. MorrisChief Medical Officer
- Nik ChetwynChief Operating Officer
- Alison Tjosvold MilhousSenior Vice President of Accounting
- Robert ShoemakerChief Scientific Officer
- Ebun S. GarnerChief Legal Officer & Corporate Secretary
- Lisa Tesvich-BonoraChief People Officer
- Brian L. BakerSenior Vice President of Finance
Principais indicadores financeiros
Resultados divulgados pela Erasca, em USD.
- Cap. de mercado
- 5,3 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -131,4 mi | -124,5 mi | |
| 0 | -179,6 mi | -161,7 mi | |
| 0 | -141,5 mi | -125 mi | |
| 0 | -247,5 mi | -242,8 mi |